Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Biomarker analysis for alectinib and bevacizumab in ALK-positive NSCLC

Trial Profile

Biomarker analysis for alectinib and bevacizumab in ALK-positive NSCLC

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Alectinib (Primary) ; Bevacizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms NLCTG1501-BM
  • Most Recent Events

    • 14 Dec 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top